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Anemia is a frequent complication in cancer patients, both at diagnosis and during treat-
ment, with a multifactorial etiology in most cases. Iron deﬁciency is among the most
common causes of anemia in this setting and can develop in nearly half of patients with
solid  tumors and hematologic malignancies. Surprisingly, this fact is usually neglected by
the attending physician in a way that proper and prompt investigation of the iron sta-
tus  is either not performed or postponed. In cancer patients, functional iron deﬁciency
is  the predominant mechanism, in which iron availability is reduced due to disease or
the therapy-related inﬂammatory process. Hence, serum ferritin is not reliable in detec-
ting  iron deﬁciency in this setting, whereas transferrin saturation seems more  appropriate
for  this purpose. Besides, lack of bioavailable iron can be further worsened by the use of
erythropoiesis stimulating agents that increase iron utilization in the bone marrow. Iron
deﬁciency can cause anemia or worsen pre-existing anemia, leading to a decline in perfor-
mance status and adherence to treatment, with possible implications in clinical outcome.
Due  to its frequency and importance, treatment of this condition is already recommended
in  many specialty guidelines and should be performed preferably with intravenous iron.
The evidences regarding the efﬁcacy of this treatment are solid, with response gain when
combined with erythropoiesis stimulating agents and signiﬁcant increments in hemoglobin
as  monotherapy. Among intravenous iron formulations, slow release preparations present
more favorable pharmacological characteristics and efﬁcacy in cancer patients.©  2016 Associac¸a˜o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by  Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Iron deﬁciency can be classiﬁed as absolute, when ironron  deﬁciency  is  common  in  cancer  patients
nemia is a frequent complication in cancer patients, both
t diagnosis and during treatment. In the European Cancer
naemia Survey (ECAS), 39% of patients were anemic at the
ime of enrollment in the study, and 67% had anemia during
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reserves are depleted, or functional, when iron reserves are
normal or even increased. The common event in both situa-
tions is the reduction of iron availability for erythropoiesis,
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Figure 1 – Prevalence of iron deﬁciency anemia (ID) and anemia in different types of tumors. GI: gastrointestinal.
and when they are, the investigation basically consists of fer-
ritin measurements, whereas transferrin saturation is rarely
used.8 This is a valid question, as among cancer patients with
Bone marrow
Fe
Hepcidin
IL-6
Marcophagesleading to anemia. In absolute deﬁciency, for obvious rea-
sons, the lack of iron in reserves is the main triggering event
of anemia. In the case of functional iron deﬁciency (FID),
although the reserves are satisfactory, the presence of an
inﬂammatory process causes the iron to become ‘trapped’
in macrophages and enterocytes, limiting its availability to
the bone marrow, triggering anemia. As expected, FID is the
predominant mechanism of iron deﬁciency associated with
cancer. The prevalence of FID in oncology patients ranges from
29 to 46%, and of iron deﬁciency associated to anemia ranges
from 7 to 42%. Figure 1 shows the prevalence of iron deﬁciency
and anemia in various types of solid tumors and hematologic
malignancies.3
Functional  iron  deﬁciency  is  the  predominant
mechanism  in  cancer  patients
The demand for iron by the bone marrow and other tissues is
supplied by the transport of this element in the circulation by
transferrin. The iron taken up by transferrin can come from
absorption by duodenal enterocytes or from recycling senes-
cent erythrocytes by macrophages. Both intestinal absorption
and macrophage release of iron are controlled by hepcidin,
a regulatory hormone synthesized by the liver, which, under
increased concentration, degrades the iron export protein, fer-
roportin, precluding the availability of iron for transportation
from these locations.4
In the presence of an inﬂammatory process, iron availabil-
ity is reduced to about 44% of the normal.5 This is due to the
release of inﬂammatory cytokines, particularly interleukin-6,
which activates the hepatic hepcidin transcription promoting
genes, increasing hepcidin concentrations, and promoting the
blockage of iron input into the circulation and reducing its
availability (Figure 2).6
Thus, even in the presence of adequate iron reserves,
cancer patients may develop lack of bioavailable iron, espe-
cially when treated with erythropoiesis stimulating agents
(ESAs) that rapidly increase the production of red blood cells
and the use of iron. This is the basic mechanism of func-
tional iron deﬁciency, the prevalence of which increases in the
more advanced stages of cancer and is associated with poorperformance status (The Eastern Cooperative Oncology Group
– ECOG).3
The  importance  of  correct  diagnosis.  .  .  what  is
there  besides  ferritin?
Traditionally, serum ferritin is the most widely used test for
the diagnosis of iron deﬁciency, due to mirroring iron reserves.
However, because it is a protein of the acute phase of inﬂam-
mation, its diagnostic applicability is considerably impaired in
the presence of acute or chronic inﬂammatory processes. In
this context, transferrin saturation (TS) becomes more  reliable
for diagnostic purposes.7
It is remarkable that, in the clinical practice, only half of
cancer patients with anemia are investigated as to iron proﬁleFigure 2 – Pathophysiology of anemia associated with
inﬂammatory process, highlighting the inhibitory action of
hepcidin on iron release. IL: interleukin.
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Figure 3 – Laboratory characteristics that differentiate absolute and functional iron deﬁciency in cancer patients; the latter
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educed transferrin saturation, more  than 80% have normal or
levated ferritin values.3
Also useful, although less available for this purpose, are the
easurements of reticulocyte hemoglobin content, determi-
ation of the percentage of hypochromic red blood cells in the
ample, soluble transferrin receptor, among others.9
Figure 3 provides a practical algorithm for differentiation
etween absolute and functional iron deﬁciency.
linical  impact  and  prognosis  of  iron  deﬁciency
n  cancer  patients
he immediate complications of iron deﬁciency is the onset or
orsening of pre-existing anemia, with varying clinical reper-
ussions, including worsening of the quality of life of the
atients. This usually affects the patients’ performance sta-
us, with the risk of jeopardizing their adherence to treatment,
nd may indirectly affect therapeutic results.3,10
he  treatment  of  iron  deﬁciency  in  cancer
atients  is  now  recommended  by  several
uidelines
urrently, the treatment of anemia in cancer patients basically
onsists of red blood cell transfusions, use of ESAs and iron
upplementation. The main therapeutic goal is to improve the
uality of life, in addition to trying to reduce the number of
lood transfusions, which are associated with the risk of trans-
itting infections, hemolytic and non-hemolytic transfusion
eactions, alloimmunization, etc.7,11In this context, the use of ESAs and iron supplementation
are effective treatment options. However, the response to
ESAs in patients undergoing chemotherapy and radiation
therapy ranges from 35 to 70%, and is limited by factors such
as iron deﬁciency, concomitant infections, neoplastic activity
and poor bone marrow reserve.7,11 Furthermore, some studies
and meta-analyzes have raised the question of the risk of
thromboembolic events with possible increases in mortal-
ity associated to the use of ESAs, especially with off-label
indications in patients who are not on chemotherapy.12
For these reasons, supplementation with iron stands as an
attractive therapeutic option, included in several guidelines
on the treatment of cancer patients with iron deﬁciency, either
as monotherapy in order to improve anemia or in association
with ESAs to enhance response to these agents (Table 1).
Intravenous  iron  is  preferred  in  the  treatment
of cancer  patients,  especially  formulations  with
slow iron  release
There are several iron dosages and formulations available
for treatment. In cancer patients, oral iron replacement is
ineffective because intestinal iron absorption is considerably
reduced in these patients, with more  than 95% of this ele-
ment being excreted in the feces. Furthermore, the small
amount of absorbed iron is ‘locked’ within the enterocytes due
to metabolic disorders induced by the previously mentioned
inﬂammatory cytokines. Another factor that impairs the out-
come is the decreased adherence to oral treatment because of
the gastrointestinal side effects.7,16
Intravenous iron, on the other hand, can overcome the
absorptive inﬂammatory blockade of iron, since the injected
328  rev bras hematol hemoter. 2 0 1 6;3  8(4):325–330
100 Only ESAs
ESAs + IV iron
Auerbach
200419
25
68
53
87
36
53
73
86
62
77
63
82
65
70
Hedenus
200722
Henry
200723
Bastit
200821
Pedrazzoli
200824
Auerbach
201020
Steensma
201125
90
80
70
60
50
40R
es
po
ns
e,
 
%
30
20
10
0
Figure 4 – Increases in hemoglobin observed with erythropoiesis stimulating agents (ESAs) alone and in combination with
intravenous iron (IV) in cancer patients.
iron is directly captured by macrophages. In case of less stable
complexes of intravenous iron, such as saccharate iron and
ferric gluconate, the carbohydrate capsule that coats the iron
is easily degraded and the iron is quickly released, requiring
multiple low-dose infusions. However, with more  stable com-
plexes, such as ferric carboxymaltose (FCM), iron release is
slow and prolonged, enabling the administration of high doses
of iron in a single infusion. Thus, 1000 mg  of iron can be admin-
istered in a single 15-min infusion without the risk of releasing
excessive iron, particularly as its free or toxic forms.7,11,16,17
Table 1 – Recommendations on monitoring and iron
replacement in cancer patients.
Guidelines Recommendations
National
Comprehensive
Cancer Network
(NCCN)13
Monotherapy with iron (preferably IV)
is recommended for absolute iron
deﬁciency (ferritin <30 ng/mL and TS
<20%) and in patients using ESAs with
ferritin between 30 and 800 ng/mL and
TS between 20 and 50%. IV iron can
reduce the number of transfusions in
patients with functional iron
deﬁciency.
American Society of
Clinical Oncology
(ASCO) and the
American Society of
Hematology (ASH)12
Iron proﬁle monitoring is
recommended. Iron replacement is
recommended if there is iron
deﬁciency, but there is not enough
evidence for greater details regarding
the form of replacement and
periodicity of monitoring.
European Society for
Medical Oncology
(ESMO)14
Iron proﬁle monitoring is
recommended. IV iron replacement in
patients with iron deﬁciency produces
increments in Hb and reduces the
need for transfusion.
European Organization
for Research and
Treatment of Cancer
(EORTC)15
Iron replacement should be restricted
to patients with absolute or functional
iron deﬁciency.
IV: intravenous; TS: transferrin saturation; ESAs: erythropoiesis
stimulating agents; Hb: hemoglobin.Thus, FCM is one of the most widely used compounds in
the treatment of iron deﬁciency in cancer patients, both in
association with ESAs and as monotherapy.
The main studies published so far, including a meta-
analysis, favor the results of the association of ESAs and
intravenous iron rather than ESA alone, because of the sharp
increase in hematologic response evidenced by the increment
in hemoglobin (Hb – Figure 4), faster response time, better
quality of life, reduced need for transfusion and dose of ESAs
when used in combination therapy.18–25
In addition to clinical beneﬁts, the treatment of chemother-
apy induced anemia using FCM was shown to be more  cost
effective, notably by reducing the use and dose of ESAs.26
Regarding the use of intravenous iron as monotherapy,
an observational study of 639 solid tumor and onco-
hematological patients showed similar increments in Hb
levels with the use of FCM alone and FCM in asso-
ciation with ESAs (1.4 g/dL and 1.6 g/dL, respectively).27
Similarly, a single dose of 1000 mg FCM in anemic patients
(Hb 8.5–10.5 g/dL, TS < 20%, ferritin > 40 ng/mL in men and
>30 ng/mL in women) with low grade non-Hodgkin’s lym-
phoma and prior chemotherapy compared to no treatment
showed greater increase in Hb (2.5 vs. 0.9 g/dL).28
A cost minimization analysis of patients scheduled for
surgery for colorectal cancer, demonstrated that the use of
FCM before surgery reduces direct and indirect costs of hos-
pitalization compared to the use of saccharate iron and oral
iron.29 This cost savings can be explained by the reduced need
for transfusion and hospitalization time; the preoperative use
of FCM was shown in another study of anemic patients in a
similar scenario.30
Conclusion
Functional iron deﬁciency, triggered by the inﬂammatory pro-
cess associated with cancer or its treatment, as well as by the
use of ESAs, is considerably common in cancer patients. As a
result, the iron proﬁle should be investigated in anemia of can-
cer patients, in which decreased transferrin saturation, even
with normal or high levels of ferritin, denotes functional iron
deﬁciency.
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The treatment of iron deﬁciency in oncology is already
ecommended by several specialty guidelines and should be
arried out preferably with intravenous iron. The evidences
egarding the efﬁcacy of this treatment are solid, with a better
esponse when combined with ESA and signiﬁcant increments
n Hb as monotherapy. Among the available intravenous iron
ormulations, FCM presents more  favorable pharmacological
haracteristics with good efﬁcacy in this inﬂammatory sce-
ario, in addition to a more  convenient dosing regimen and
ood cost-effective ratio, as a smaller number of transfusions
nd lower doses of ESA are required.
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